Celcuity Q3 net loss $29.8M ($0.70/sh); VIKTORIA-1 wild-type cohort 100% enrolled

Celcuity Inc.

2024-Q3 EPS reported -$1.96

PIK3CA wild-type cohort of VIKTORIA-1 100% enrolled; topline data expected late Q1 2025 or Q2 2025.
Celcuity reports Q3 2024 net loss $29.8M ($0.70/sh) vs $18.4M ($0.83/sh) in Q3 2023.
R&D expenses $27.6M, up from $17.5M; total operating expenses $30.1M.
Cash, cash equivalents and investments ~$264M at end of Q3 2024, expected to fund through 2026.
VIKTORIA-2 Phase 3 first patient enrollment expected Q2 2025; Phase 1b/2 mCRPC data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.